Early HER2+ breast cancer: escalate, de-escalate or personalize?
Two international breast cancer experts explore one of the most important clinical questions in modern oncology: balancing cure, toxicity and personalization in HER2-positive early breast cancer.
In this discussion
- What are we truly trying to achieve in HER2-positive early breast cancer?
- Preventing recurrence and metastatic progression
- Escalation and de-escalation in stage I disease
- The evolving role of the APT regimen
- Insights from PHERGain-2
- ATEMPT and ATEMPT 2.0 trial updates
- What DESTINY-Breast11 and DESTINY-Breast05 mean for practice
- Subcutaneous or intravenous HER2-targeted therapy
- Quality of life, less toxicity and patient-centered care
- The future of truly personalized HER2-positive treatment
